[Effect of Penehyclidine hydrochloride in systemic inflammatory response syndrome caused by cardiopulmonary bypass]

To investigate whether Penehyclidine hydrochloride has effect on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass.

40 rheumatic heart disease patients undergoing CPB were randomly divided into Penehyclidine hydrochloride (P) group and control (C) group (20 patients in each group). In group P, intravenous drip of 0.01 mg/kg of Penehyclidine hydrochloride injection was given before anesthesia, and 0. 015 mg/kg of Penehyclidine hydrochloride was added into initial volume of CPB. While in control group, 0.9% NaCl solution was given instead of injection as a placebo. Blood samples were taken before anesthesia (T0), 30 min after CPB (T1), 10 min after aortic off-clamping (T2) and 2 hours when CPB was over (T3). Interleukin-6 (IL-6), tumornecross alpha (TNF-alpha) levels were detected by ELISA. The morbility of pneumonia and SIRS caused by CPB was also evaluated.

At T2 and T3, the IL-6 level was higher than T0 and T1 both in group C and group P (P < 0.05). At T2 and T3, the IL-6 level in group C was higher than that of group P (P < 0.05). The TNF-alpha level at T3 was lower than at T1 and T2 in group P (P < 0.05). There was no significant difference between group P and group C at each time point (P > 0.05). The morbility of pneumonia and SIRS was higher in group C (P < 0.05).

Penehyclidine hydrochloride can decrease the levels of proinflamnlatory cytokines in plasma and therefore attenuate the morbility of pneumonia and SIRS caused by CPB.